Scientific Foundation and Core Technology

The core therapeutic strategy of SemaThera revolves around the pharmacological modulation of Semaphorins—specifically Semaphorin 3A (SEMA3A)—which are guidance cues traditionally known for their role in embryonic development. In adults, particularly under pathological conditions such as chronic diabetes, SEMA3A levels become pathologically elevated in the eye's vitreous.

SemaThera’s scientific approach establishes that high levels of SEMA3A act as a chemical barrier that hinders normal vascular regeneration, compromises vascular barrier function, increases vascular permeability, and recruits destructive inflammatory cells into the retina. This process results in ischemia, fluid leakage, and progressive vision loss.

To counteract this mechanism, SemaThera has engineered a proprietary class of biologic products designed to intercept and neutralize disease-driving proteins:

• Proprietary Biological Traps: SemaThera has developed a specialized family of biological traps that selectively bind and sequester SEMA3A and related cytokines.
• In Vivo Neutralization: Pre-clinical studies utilizing orthologous models of retinal vascular disease have demonstrated that these biological traps successfully neutralize SEMA3A in vivo.
• Restoration of Vascular Health: By neutralizing SEMA3A, SemaThera’s therapies eliminate the vasorepulsive barrier, facilitating physiological re-vascularization of ischemic retinal zones, significantly cutting down retinal vascular leakage, and suppressing destructive inflammation.

Products and Pipeline Offerings

SemaThera’s product pipeline targets conditions that currently have limited or suboptimal treatment options, particularly for patient populations unresponsive to standard anti-VEGF (Vascular Endothelial Growth Factor) therapies.

• Anti-SEMA3A Biological Therapies for Diabetic Retinopathy (DR): Diabetic retinopathy is a leading cause of blindness in working-age adults. SemaThera’s lead assets focus on preventing and reversing the microvascular damage characteristic of DR.
• Diabetic Macular Edema (DME) Treatments: By repairing vascular barrier integrity and stopping fluid leakage into the macula, SemaThera’s biological traps aim to improve or stabilize visual acuity in DME patients.
• Wet Age-Related Macular Degeneration (Wet AMD) Solutions: The company is expanding the application of its SEMA3A-targeting platform to address other ischemic and neovascular retinal disorders like wet AMD, where abnormal blood vessel growth threatens central vision.

Strategic Collaborations and Research Growth

SemaThera actively builds industry partnerships to accelerate the clinical translation of its pipeline. A notable milestone includes entering into a research collaboration and exclusive license agreement with global healthcare leader Roche, validating the therapeutic potential of its anti-semaphorin platform. Supported by prominent scientific founders and robust pre-clinical data, SemaThera continues to advance its biologic candidates toward clinical trials, positioning itself as a leader in the specialized field of retinal vascular repair.